{"page_num": 1, "text": "Ruitang Deng, Ph.D.\nBPS 437\nBiomedical and Pharmaceutical Sciences\nCollege of Pharmacy, University of Rhode Island\nMenopause and Osteoporosis"}
{"page_num": 2, "text": "What is Osteoporosis?\nDefinition: A silent disease characterized by low bone mass \nand structural deterioration of bone tissue with an increase in \nbone fragility and susceptibility to fracture \n➢World-wide, 1 in 3 women and 1 \nin 5 men are at risk of an \nosteoporotic fracture\n➢In fact, osteoporotic fracture is \nestimated to occur every 3 \nsecond\n➢The most common fractures \noccur at the hip, spine and wrist.\nthe spongy hole of bones increase in size (more porous); more susceptible to fracture"}
{"page_num": 3, "text": "Age (years)\n0        10       20      30       40     50       60      70      80   Age (years) \nBone Mass vs Estrogen levels  during the Aging\nincreasing bone size and childhood-\npuberty match\npeak bone mass at ages 15-40 when \nsexually mature\naccelerated loss begins at menopause ~50 \nyo; gradual loss in elderly"}
{"page_num": 4, "text": "Bone, Calcium and Hormones\nCalcium Atom\nFile:Illu thyroid parathyroid.jpg\nHormones\nBone"}
{"page_num": 5, "text": "❖  Structural function: providing mobility, support, and protection for the body\n❖  Reservoir function, as the storehouse for essential minerals. \n❖  It is not a static organ, but is constantly changing\nBone: Overview\nFunctions: \nComposition:\n❖ Crystals of mineral: Calcium and Phosphorus which bind to protein. \n❖  Protein: Mainly collagen\n❖  Make bone have both strength and resilience (plasticity)\nTreated with bleach \n(hypochlorite) to digest \ncollagen, leaving mineral \ncomponent intact\nTreated with hydrochloric \nacid to dissolve mineral,\nleaving collagen \ncomponent intact\nparticularly with calcium"}
{"page_num": 6, "text": "Bone Macro-structure"}
{"page_num": 7, "text": "File:Transverse Section Of Bone.png\nBone Micro-structure"}
{"page_num": 8, "text": "Bone is a Dynamic Tissue: Bone Modeling\nBone Modeling\nSurface\nInside\nOld bone \ndissolved\nNew bone \nformed\n❖  Bone growth during childhood: Resorption occurs inside the \n     bone while formation of new bone occurs on its surface\n❖  Allow bone to grow in size and to shift in space\nosteoclasts dissolve the bone \n\"from inside\"\nosteoblasts create new bone \nfrom the surface, on the outside\nby osteoclast\nby osteoblast"}
{"page_num": 9, "text": "Bone is Dynamic Tissue: Bone Remodeling\n❖  Bone goes continuous remodeling process through dissolving old \n     bone and replacing with new bone\n❖  Occurs throughout life and becomes the dominant process by the \n     time that bone reaches its peak mass (typically by the early 20s).\n❖  Such remodeling function is carried out by a team of cells, called \n     basic multicellular unit (BMU)\n❖  BMU moves on the surface of bone as remodeling continues\nBone Remodeling\n❖  Remodeling repairs the damage to the skeleton that can result \n     from repeated stresses by replacing small cracks or deformities \n     in areas of cell damage. \n❖  Remodeling also prevents the accumulation of too much old \n     bone, which can lose its resilience and become brittle.\n❖  Remodeling is also important for the function of the skeleton as \n     the bank for calcium and phosphorus.\nWhy Remodeling?\npeaks at early 20 and does not grow anymore"}
{"page_num": 10, "text": "Basic Multicellular Unit (BMU)\nBMU\ncoordination of BMU is key; \nif osteoclast dissolves fast, and osteoblast does not build new bone fast enough, can lead to weak bone"}
{"page_num": 11, "text": "Adult bone remodeling\n• Lifespan of BMU ~ 6-9 months\n• Moving speed ~ 25 mm/day\n• Interval between successive remodeling events\n  at the same location ~ 2-5 years\n• Rate of turnover of whole skeleton ~ 10% per year\nParfitt, 1993\nBasic Multicellular Unit (BMU): Overview"}
{"page_num": 12, "text": "Cells Involving in Bone Modeling and Remodeling\n❖  Large cells that \n     dissolve the bone. \n❖  Formed from two \n     or more cells that \n     fuse together, so \n     the osteoclasts \n     usually have more \n     than one nucleus. \n❖  Derived from the \n     bone marrow and  \n     are related to white \n     blood cells.\nOsteoclasts\nRANK: Receptor Activator of Nuclear Factor κ B \nOPG: Osteoprotegerin \nM-CSF: Macrophage colony-stimulating factor\nRANK ligand on osteoblast simulate osteoclast-gen"}
{"page_num": 13, "text": "❖  Cells that form new bone\n❖  Derived from the bone marrow and are related to structural cells\n❖  They have only one nucleus\n❖  Producing new bone called \"osteoid\" which is made of \n     bone collagen and other proteins. \n❖  Controlling calcium and mineral deposition. \nOsteoblasts\nCells Involving in Bone Modeling and Remodeling\nMsx2\nDlx5/6\nRunx2\nOsx\nFosB/Fra1\nMesenchymal\nprogenitors\nOsteoblasts\nPre-osteoblasts\nRunx2\nOsx\nOsx: Osterix\nRunx2: Runt-related transcription factor 2\nMsx2: msh homeobox 2\nDlx5/6: Drosophila distal-less  gene 5/6"}
{"page_num": 14, "text": "Cells Involving in Bone Modeling and Remodeling\n❖  Cells inside the bone. \n❖  They also come from osteoblasts. \n❖  Networked to each other via long cytoplasmic extensions \n     that occupy tiny canals called canaliculi\n❖  Sensing pressures or cracks in the bone and help to direct \n     where osteoclasts will dissolve the bone. \n❖  Sitting on surface\n❖  Derived from osteoblasts when new bone is formed\n❖  Regulating passage of calcium into and out of the bone\n❖  Responding to hormones by making special proteins that \n     activate the osteoclasts. \nLining Cells\nOsteocytes"}
{"page_num": 15, "text": "Bone Disorders\nOsteoporosis: \n❖  Primary: being age-related osteoporosis, such as \npostmenopausal osteoporosis or unknow causes\n❖  Secondary: the loss of bone is caused by certain lifestyle \nbehaviors, diseases or medications. 20% to 30% of \npostmenopausal women and more than 50% of men with \nosteoporosis have a secondary cause. \n•Adverse effects of drug therapy\n•Endocrine disorders\n•Eating disorders\n•Immobilization\n•Marrow-related disorders \n•Disorders of the gastrointestinal or biliary tract\n•Renal disease, \n•Cancer\n•Organ transplantation"}
{"page_num": 16, "text": "Other Bone Disorders:\n❖  Primary hyperparathyroidism: due to high levels of PTH\n❖  Paget’s Disease: due to defect or interfering with normal bone \nremodeling process (generating new bone faster than normal), the rapid \nremodeling produces bone that's less organized and weaker than normal \nbone, which can lead to bone pain, deformities and fractures\n❖  Renal Osteodystrophy: a form of metabolic bone disease seen in \npatients with chronic renal insufficiency characterized by bone \nmineralization deficiency due to electrolyte and endocrine abnormalities\n❖  Rickets and Osteomalacia: Rickets is a condition that affects bone \ndevelopment in children. It causes bone pain, poor growth and soft, weak \nbones that can lead to bone deformities. Adults can experience a similar \ncondition, which is known as osteomalacia or soft bones.\n❖  Osteogenesis Imperfecta: a group of genetic disorders that all result \nin bone that breaks easily. a problem with connective tissue due to a lack \nof, or poorly formed, type I collagen\nBone Disorders"}
{"page_num": 17, "text": "Anabolic Agents (Building bone)\n❖  Parathyroid hormone (PTH): Teriparatide (Forteo) \n❖ PTH-related protein: Abaloparatide (Tymlos)\n❖  Romosozumab (Evenity)\nAntiresorptive Agents (Reducing bone loss)\n❖  Bisphosphonates\n❖  Hormone or estrogen replacement\n❖  Selective estrogen receptor modulators (SERMs) (raloxifene)\n❖  Calcitonin\n❖  Denosumab (Prolia or Xgeva)\n❖ Romosozumab (Evenity)\nTreatments for Osteoporosis\nparadoxical building bone effect of intermittent PTH\nromosozumab dual action of building bone and reduce loss"}
{"page_num": 18, "text": "Anabolic Therapy with PTH: A Paradox\nThis paradox—the fact that PTH secreted continuously can break down bone \nwhile intermittent injections of the same hormone actually build bone-has never \nbeen fully explained. \nIncreasing blood calcium \nlevels by stimulating \nosteoclasts to break down \nbone and release calcium\nbone\nIncreasing \ngastrointestinal \ncalcium absorption by \nactivating Vitamin D\nPromoting calcium \nuptake by the kidneys\n564,691\nPTH\nTeriparatide (Forteo)"}
{"page_num": 19, "text": "PTH-related protein (PTHrP): Abaloparatide (Tymlos)\n▪\nMainly made and secreted by mesenchymal stem cells\n▪\nOccasionally made and secreted by cancer cells\n▪\nBinding to the same receptor as PTH\nAnabolic Therapy \nPTH\nPTHrP\nParathyroid Hormone 1 \nReceptor (PTH1R)\nIntermittent\ninjection \nEnhancing new \nbone building\npartially matching AA sequence with PTH"}
{"page_num": 20, "text": "Romosozumab: Function and Mechanism\n❖  A humanized monoclonal antibody\n❖  Specifically targets to sclerostin, an inhibitor of Wnt \n     pathway signaling\n❖  Increasing bone formation and decreasing bone resorption.\n❖  Approved by FDA in 2019\nsclerostin's dual effect of promoting osteoclast and inhibiting osteoblast; thus \nintercepting sclerostin allow increase bone formation and decrease breakdown"}
{"page_num": 21, "text": "basic structure of bisphosphonates\nAll bisphosphonate \ndrugs share a common \nP-C-P \"backbone \nFile:Bisphosphonate side chains.png\nNon-N-containing bisphosphonates\n❖  Etidronate  - 1 (relative potency)\n❖  Clodronate - 10 \n❖  Tiludronate - 10 \nN-containing bisphosphonates\n❖  Pamidronate - 100 \n❖  Neridronate - 100 \n❖  Olpadronate - 500 \n❖  Alendronate - 500 \n❖  Ibandronate - 1000 \n❖  Risedronate - 2000 \n❖  Zoledronate - 10000 \nAntiresorptive Agents: Bisphosphonates"}
{"page_num": 22, "text": "Bisphosphonates: Mechanisms of Action\nNon-N-containing bisphosphonates \nBisphosphonates\nATP analog\nCompeting with ATP\nApoptosis of osteoclasts\nBisphosphonates have high affinity with bone and when \nattached to bone tissue, they are \"ingested\" by osteoclasts"}
{"page_num": 23, "text": "FPPS: farnesyl diphosphate synthase \nHMG-CoA: 3-hydroxy-3-methyl-glutaryl-CoA reductase \nHMG-CoA\nMevalonic \nAcid\nGeranyl \npyrophosphate\nFarnesyl \npyrophosphate\nInhibiting \nosteoclastogensis \nand inducing \napoptosis\nFPPS\nFPPS\nN-containing bisphosphonates\nInhibits\nN-containing bisphosphonates \nBisphosphonates: Mechanisms of Action"}
{"page_num": 24, "text": "Androgen\nEstrogen\nEstrogen alone or a combination of estrogen and progestin\nAntiresorptive Agents:Hormone Replacement \nTherapy (HRT)\nNote: Androgen \ntestosterone may \nbe used for treating \nosteoporosis in men\nmain target effect produced by ER-alpha\nincrease cortical BMD/thickness, \ntrabecular number/thickness\nER-alpha-induced apoptosis of \nosteoclasts"}
{"page_num": 25, "text": "Sex Steroids and Bone: Mechanism\nEstrogen\nEstrogen Receptor\n(ER) in Osteoclasts\nFas/FASL \nApoptosis of \nosteoclasts\nSuppression of \nbone resorption \nPrevention \nof bone loss\nAndrogen\ndeath receptor interaction"}
{"page_num": 26, "text": "Antiresorptive Agents: Tibolone\nA selective tissue estrogenic activity regulator (STEAR)\nNote: Other tibolone \nmetabolites have \nagonistic activity to \nprogesterone and \nandrogen receptor. \nTibolone\n3-hydroxytibolone\n3-hydroxytibolone\nEstrogen receptor alpha (ER)\nReducing bone loss\nMaintaining healthy bone\ndifferent to estrogen receptor modulator because this \n\"Regulator\" can also have pleiotropic effects on other \nreceptors (e.g. progesterone, androgen receptors)"}
{"page_num": 27, "text": "Antiresorptive Agents: Selective Estrogen \nReceptor Modulators (SERMs)\nRaloxifene\nRaloxifene\nEstrogen receptor \nalpha (ER) in bone\nReducing bone loss\nMaintaining healthy bone\nAgonistic activity\nER in breast \nand uterus\nAntagonistic \nactivity\nReduced side \neffects in those \ntissues\nsimultaneous dual mechanism depending on tissue \ntype; \nagonistic on bone, but antagonistic in breast/uterus \n(reduced risk of breast/endometrial cancer)\nmodulator specific to estrogen receptor, no affinity to other receptors such as progesterone \nandrogen unlike regulator"}
{"page_num": 28, "text": "Calcitonin receptor\nA GPCR with Gs\nActivating AC/cAMP \nsignaling pathway\nInhibits osteoclast activity \nand slow bone breakdown \nAntiresorptive Agents: Calcitonin\nCalcitonin\nNote: This drug is safer but \nless effective than other \nosteoporosis medications. \nFor that reason, it's \nconsidered to be one of the \nlast treatment options. \nnot as potent; so reserved as last line, not \nresponding to previous agents"}
{"page_num": 29, "text": "Denosumab: Function and Mechanism\n❖  Formerly known as AMG 162\n❖  A fully-humanized monoclonal antibody\n❖  Specifically targets to RANKL to block \n     the osteoclastogenesis\nProduction of \nRANKL and \nosteoprotegerin \n(OPG)\nOsteoclast \nprecursors \nOsteoclasts\nRANK: Receptor Activator of Nuclear Factor κ B \nRANKL: RANK ligand\nDenosumab\nblock the RANK ligand signaling by osteoblasts; prevent activation of osteoclast precursors"}
{"page_num": 30, "text": "➢Adequate calcium supplement\n➢Vitamin D intake\n➢Weight-bearing exercise\n➢Smoking cessation\n➢Limitation of alcohol/caffeine \nconsumption\n➢Fall-prevention techniques.\nNonpharmacological management \nof osteoporosis \nassociated reduce calcium uptake from the diet"}
{"page_num": 31, "text": "Primary hyperparathyroidism \n❖  Removal of parathyroid adenoma(s) by surgery \n❖  Hormone therapy \n❖  Bisphosphonates\nRenal osteodystrophy (bone disease from kidney failure) \n❖  Treatment of kidney problem (dialysis, transplantation)\n❖  Special diets\n❖  Calcitriol \nPaget’s disease of bone \n❖  Bisphosphonates (alendronate, risedronate, tiludronate, etidronate)\nOsteogenesis imperfecta \n❖  Rehabilitation\n❖  Physical therapy\n❖  Bisphosphonates\nRickets and Osteomalacia\n❖  Vitamin D\n❖  Calcium\nTreatment of Other Bone Disorders"}
{"page_num": 32, "text": "Combination Therapies\n❖  Bisphosphonates with hormone therapy\n❖  Anti-absorptive Agents with anabolic PTH\n❖  Drug therapy with calcium and Vitamin D\n❖  Therapy with Dietary supplements\nDrugs with different mechanisms of action \nare combined as combinational therapies\ncombination of anabolic + anti-reabsorptive therapy\nnote: dual action of romosozumab"}
